About Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Industry, Sector and Symbol
Trailing P/E Ratio-6.5025088320484
Forward P/E Ratio-4.28
Sales & Book Value
Price / Sales1,214.92
Price / CashN/A
Book Value$2.90 per share
Price / Book8.91
Return on Equity-95.30%
Return on Assets-59.49%
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its quarterly earnings data on Thursday, February, 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.09. The specialty pharmaceutical company earned $0.57 million during the quarter, compared to analyst estimates of $0.84 million. The business's revenue was up 1435.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.68) earnings per share. View Adamas Pharmaceuticals' Earnings History.
Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2018?
9 Wall Street analysts have issued 1 year price targets for Adamas Pharmaceuticals' shares. Their forecasts range from $33.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $46.00 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (2/23/2018)
- 2. Mizuho analysts commented, "We think the timing of the financing (in front of early Gocovri commercial updates) is ideal, and should allow shares to rebound quickly. There is an additional $12.75M greenshoe option that we expect to be filled as well. The company indicated it had $176.4M in cash/investments on its balance sheet as of December 31, 2017, up from $130.7M in cash at the end of 3Q:17, and also received a $65M payment from Healthcare Royalty Partners in 4Q:17. We estimate that Adamas therefore used ~$19.3M in cash in 4Q:17 and should have ~$270M in cash after the equity financing (with no additional financing needs this year). Because we believe that Adamas is a likely takeout target during a period of increased M&A activity and higher CNS valuations, it is possible that this could be its last financing event. We continue to view ADMS as our top pick in 2018, and reiterate our Buy rating." (1/23/2018)
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Mallinckrodt (MNK), AxoGen (AXGN), CytomX Therapeutics (CTMX), Epizyme (EPZM), Apellis Pharmaceuticals (APLS), Intra-Cellular Therapies (ITCI), Prothena (PRTA), PTC Therapeutics (PTCT), Pacira Pharmaceuticals (PCRX), Arena Pharmaceuticals (ARNA), G1 Therapeutics (GTHX), Assembly Biosciences (ASMB), Cellectis (CLLS), Genomic Health (GHDX), Acorda Therapeutics (ACOR), Revance Therapeutics (RVNC), Wave Life Sciences (WVE) and TherapeuticsMD (TXMD).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Gregory T. Went Ph.D., Chairman of the Board, Chief Executive Officer, Co-Founder (Age 53)
- Alfred G. Merriweather, Chief Financial Officer (Age 63)
- Richard A. King, Chief Operating Officer (Age 52)
- Leonie McConville, Senior Vice President - Human Resources (Age 53)
- Christopher B. Prentiss, Principal Accounting Officer (Age 42)
- Jennifer J. Rhodes, Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer (Age 47)
- Martin Forrest, Vice President, Corporate Communications and Investor Relations
- Rajiv Patni M.D., Chief Medical Officer (Age 48)
- David L. Mahoney, Lead Independent Director (Age 62)
- Mardi C. Dier, Director (Age 53)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
Media headlines about ADMS stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 52.01 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.14%), Brenner West Capital Advisors LP (4.85%), Macquarie Group Ltd. (3.40%), Alliancebernstein L.P. (2.51%), Millennium Management LLC (2.51%) and Emerald Advisers Inc. PA (2.11%). Company insiders that own Adamas Pharmaceuticals stock include Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Which institutional investors are selling Adamas Pharmaceuticals stock?
ADMS stock was sold by a variety of institutional investors in the last quarter, including Kerrisdale Advisers LLC, Millennium Management LLC, Brenner West Capital Advisors LP, Cheyne Capital Management UK LLP, Granite Point Capital Management L.P., Mosaic Family Wealth LLC, TIAA CREF Investment Management LLC and BlackRock Inc.. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.
Which institutional investors are buying Adamas Pharmaceuticals stock?
ADMS stock was acquired by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Driehaus Capital Management LLC, UBS Asset Management Americas Inc., Ardsley Advisory Partners, Macquarie Group Ltd., Deltec Asset Management LLC, Tamarack Advisers LP and Alliancebernstein L.P.. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $25.83.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $699.40 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adamas Pharmaceuticals (NASDAQ:ADMS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$46.00||$45.67||$45.67||$40.80|
|Price Target Upside: ||78.09% upside||7.07% upside||43.92% upside||91.55% upside|
Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History
Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History
(Data available from 3/21/2016 forward)
Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings History and Estimates Chart
Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/22/2018||Q4 2017||($1.18)||($1.27)||$0.84 million||$0.57 million||View||N/A|
|11/2/2017||Q3 2017||($1.01)||($1.04)||$0.03 million||View||N/A|
|8/8/2017||Q2 2017||($0.81)||($0.93)||$0.03 million||$0.02 million||View||Listen|
|5/9/2017||Q1 2017||($0.72)||($0.72)||$0.11 million||View||Listen|
|2/28/2017||Q4||($0.80)||($0.68)||$0.17 million||$0.04 million||View||N/A|
|11/3/2016||Q3 2016||($0.83)||($0.66)||$0.26 million||$0.14 million||View||N/A|
|8/4/2016||Q2 2016||($0.71)||($0.78)||$0.18 million||$0.22 million||View||N/A|
|2/23/2016||Q4||($0.81)||($0.58)||$0.10 million||$0.52 million||View||N/A|
|11/12/2015||Q3||($0.79)||($0.81)||$0.10 million||$0.77 million||View||N/A|
|8/11/2015||Q215||($0.67)||($0.78)||$0.10 million||$0.40 million||View||N/A|
|5/13/2015||Q414||($0.74)||($0.69)||$0.10 million||$0.23 million||View||N/A|
|3/3/2015||Q4 2014||$0.64||$0.50||$30.18 million||$30.30 million||View||N/A|
|11/4/2014||Q314||($0.44)||($0.57)||$0.18 million||$0.22 million||View||N/A|
|8/7/2014||Q214||$2.07||$0.88||$18.75 million||$25.15 million||View||N/A|
|5/13/2014||Q114||($0.09)||($0.67)||$30.60 million||$0.18 million||View||N/A|
Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates
Current Year EPS Consensus Estimate: $-6.03 EPS
Next Year EPS Consensus Estimate: $-4.03 EPS
Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 77.25%
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/21/2017||Jennifer J. Rhodes||Insider||Sell||440||$32.30||$14,212.00|| |
|6/21/2017||Great Point Partners Llc||Major Shareholder||Sell||380,000||$17.08||$6,490,400.00|| |
|6/21/2017||Jennifer J. Rhodes||Insider||Sell||1,041||$17.53||$18,248.73|| |
|6/19/2017||Great Point Partners Llc||Major Shareholder||Sell||350,000||$17.05||$5,967,500.00|| |
|3/21/2017||Gregory T Went||CEO||Sell||2,807||$17.03||$47,803.21||166,526|| |
|3/21/2017||Rajiv Patni||Insider||Sell||733||$17.04||$12,490.32||13,642|| |
|3/21/2017||William J Dawson||CFO||Sell||716||$17.02||$12,186.32||14,284|| |
|9/16/2016||Ix Lp Mdv||Major Shareholder||Buy||62,977||$16.48||$1,037,860.96|| |
|9/13/2016||Ix Lp Mdv||Major Shareholder||Buy||84,376||$15.58||$1,314,578.08|| |
|9/7/2016||William W Ericson||Director||Buy||60,846||$15.68||$954,065.28|| |
|9/6/2016||Ix Lp Mdv||Major Shareholder||Buy||50,919||$14.79||$753,092.01|| |
|9/6/2016||William W Ericson||Director||Buy||7,200||$15.00||$108,000.00|| |
|9/2/2016||William W Ericson||Director||Buy||43,719||$14.75||$644,855.25|| |
|4/18/2016||Natalie Mcclure||SVP||Sell||36,000||$18.50||$666,000.00||21,006|| |
|12/7/2015||Ivan M Lieberburg||Director||Sell||3,000||$16.23||$48,690.00||48,000|| |
|10/5/2015||Ivan M Lieberburg||Director||Sell||3,000||$16.75||$50,250.00||54,000|| |
|9/8/2015||Ivan M Lieberburg||Director||Sell||3,000||$19.13||$57,390.00||57,000|| |
|7/6/2015||Ivan M Lieberburg||Director||Sell||3,000||$25.91||$77,730.00|| |
|6/5/2015||Natalie Mcclure||SVP||Sell||2,000||$18.95||$37,900.00|| |
|5/18/2015||Ix Lp Mdv||Major Shareholder||Sell||1,643||$18.04||$29,639.72|| |
|5/15/2015||Richard H Booth||Director||Sell||1,000||$17.85||$17,850.00|| |
|5/14/2015||Gregory T Went||CEO||Sell||2,728||$18.00||$49,104.00|| |
|4/23/2015||Gregory T Went||CEO||Sell||3,300||$18.00||$59,400.00|| |
|4/21/2015||Gregory T Went||CEO||Sell||962||$18.01||$17,325.62|| |
|4/20/2015||Gregory T Went||CEO||Sell||2,610||$18.00||$46,980.00|| |
|4/15/2015||Richard H Booth||Director||Sell||1,000||$17.72||$17,720.00|| |
|4/14/2015||Gregory T Went||CEO||Sell||14,757||$7.15||$105,512.55|| |
|4/10/2015||William W Ericson||Director||Sell||37,078||$18.56||$688,167.68|| |
|4/6/2015||Ivan M Lieberburg||Director||Sell||3,000||$17.44||$52,320.00|| |
|4/6/2015||Natalie Mcclure||SVP||Sell||2,000||$17.44||$34,880.00|| |
|3/19/2015||Gregory T Went||CEO||Sell||23,088||$18.00||$415,584.00|| |
|3/18/2015||Ix Lp Mdv||Major Shareholder||Sell||11,723||$18.02||$211,248.46|| |
|3/16/2015||Richard H Booth||Director||Sell||1,000||$17.36||$17,360.00|| |
|3/13/2015||Aeris Capital Equity Investmen||Major Shareholder||Sell||350,000||$17.23||$6,030,500.00|| |
|2/17/2015||Richard H Booth||Director||Sell||1,000||$16.54||$16,540.00|| |
|2/5/2015||Natalie Mcclure||SVP||Sell||2,000||$16.87||$33,740.00|| |
|2/2/2015||Ivan M Lieberburg||Director||Sell||3,000||$16.77||$50,310.00|| |
|1/5/2015||Ivan M Lieberburg||Director||Sell||3,000||$17.59||$52,770.00|| |
|1/5/2015||Natalie Mcclure||SVP||Sell||2,000||$17.59||$35,180.00|| |
|12/24/2014||Richard H Booth||Director||Sell||2,000||$17.51||$35,020.00|| |
|12/3/2014||Aeris Capital Equity Investmen||Major Shareholder||Sell||111,625||$14.51||$1,619,678.75|| |
|12/1/2014||Aeris Capital Equity Investmen||Major Shareholder||Sell||13,615||$14.54||$197,962.10|| |
|12/1/2014||Natalie Mcclure||SVP||Sell||20,000||$14.50||$290,000.00|| |
|11/26/2014||Aeris Capital Equity Investmen||Major Shareholder||Sell||12,500||$14.77||$184,625.00|| |
|11/25/2014||Aeris Capital Equity Investmen||Major Shareholder||Sell||10,000||$14.85||$148,500.00|| |
|4/15/2014||William W Ericson||Director||Buy||300,000||$16.00||$4,800,000.00|| |
Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines
Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement
Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Wednesday, March, 21, 2018